[Efficacy and Safety of Reduced Dose Azacitidine in the Treatment of Elderly Patients with Myelodysplastic Syndromes].

Cong ZhangCai SunDe-Zhen WangZhan-Wei LiuTing Fang

Published in: Zhongguo shi yan xue ye xue za zhi (2024)

Elderly patients with MDS have poor tolerance to chemotherapy. Reducing azacitidine in the treatment of elderly MDS patients shows good efficacy and safety.

Keyphrases

middle aged
acute myeloid leukemia
end stage renal disease
ejection fraction
community dwelling
newly diagnosed
peritoneal dialysis
squamous cell carcinoma
prognostic factors
radiation therapy
patient reported outcomes
patient reported